A growing number of targeted drugs, such as abatacept (ABA), which blocks T‐cell co‐stimulatory signalling, and tumour necrosis factor inhibitors (TNFi), which antagonise TNF‐α, have been demonstrated to suppress the synthesis of cytokines for the treatment of RA.17, 18. Here, TNF is linked to rheumatoid arthritis.